Sandoz (SDZ) confirms approval of Ondibta by the EU Commission; strengthening their overall Biosimilars leadership and position in diabetes

Sandoz's confirmation of EU approval for Ondibta is a pivotal development, reinforcing its leadership in the biosimilars market, especially in diabetes care.

Newsquawk StaffPublished On the live feed at 4 more headlines followed before this page went public
Newsquawk headlinesUTC

HSBC (HSBA LN) is reportedly considering the sale of its Singaporean insurance business, according to sources

SLB (SLB) is poised to reap gains from Trump’s plan to leverage Venezuelan oil, is in position to win some of the first contracts under plan to revive Venezuela’s ailing oil industry, FT reports

Sandoz (SDZ) confirms approval of Ondibta by the EU Commission; strengthening their overall Biosimilars leadership and position in diabetes

China's State Administration for Market Regulation has commenced an investigation on Trip.com (TCOM) under anti-monopoly laws of PRC; Trip says it is cooperating, business operations remain normal

Russian Foreign Minister Lavrov says, regarding reports that US ambassadors could visit Moscow, says President Putin is willing to have serious talks. Discussion of a Ukraine ceasefire is not serious.

Open the platform and use it. The whole workspace is free to try, with no signup and no card. When you want the headlines arriving live instead of on a delay, Newsquawk Pro is £24.99 for 7 days.

Free. No signup, no card.
Context

This move could enhance Sandoz's competitive edge, potentially driving stock performance and investor interest in the broader pharmaceutical sector, particularly among peers focusing on diabetes treatments.

Related headlines

The whole workspace, free to try.

Try it free